Why Clopidogrel is Stopped One Year After Coronary Stent Placement
Clopidogrel is typically stopped at 12 months after coronary stent placement because this duration balances the prevention of stent thrombosis (which peaks in the first year) against the ongoing risk of bleeding from prolonged dual antiplatelet therapy (DAPT), with most guidelines establishing 12 months as the minimum recommended duration for drug-eluting stents in patients not at high bleeding risk. 1
The Evidence-Based Rationale
Stent Thrombosis Risk Timeline
The risk of stent thrombosis is highest in the first year after stent placement, particularly in the first 6 months. Premature discontinuation of clopidogrel before 12 months is one of the strongest predictors of catastrophic stent thrombosis, with studies showing hazard ratios as high as 161 for subacute stent thrombosis and 57 for late stent thrombosis when antiplatelet therapy is stopped early 2. In one observational study, a striking 29% of patients who discontinued antiplatelet therapy prematurely experienced stent thrombosis 2.
After 12 months, the stent endothelializes sufficiently that the thrombosis risk decreases substantially, though it never completely disappears. This is why aspirin is continued indefinitely while clopidogrel can be stopped 1.
Bleeding Risk Accumulation
The longer patients remain on DAPT, the more they accumulate bleeding risk. The guidelines explicitly recognize this trade-off: "If the risk of morbidity from bleeding outweighs the anticipated benefit afforded by a recommended duration of P2Y12 inhibitor therapy after stent implantation, earlier discontinuation (e.g., <12 months) of P2Y12 inhibitor therapy is reasonable" 1.
Stent Type Matters
The 12-month recommendation applies primarily to:
- Drug-eluting stents (DES) for any indication: minimum 12 months if not at high bleeding risk 1
- Any stent (BMS or DES) placed for acute coronary syndrome: at least 12 months 1, 3
For bare-metal stents (BMS) in stable patients, the minimum is only 1 month, ideally extended to 12 months unless bleeding risk is high 1.
Important Clinical Nuances
When to Continue Beyond 12 Months
Continuation beyond 12 months "may be considered" (Class IIb recommendation) but is not routinely recommended 1. Consider extending DAPT in:
- Patients with previous stent thrombosis
- Left main coronary artery stenting
- Multivessel stenting
- Stent in the only remaining patent vessel
- Complex PCI (bifurcation lesions, long stents, overlapping stents) 4, 5
However, the OPTIDUAL trial showed that extended DAPT beyond 12 months did not achieve superiority in reducing net adverse clinical events 6, reinforcing that 12 months is generally sufficient.
Critical Pitfall: Never Stop Without Cardiologist Discussion
Patients must be counseled that DAPT should never be discontinued before discussion with their cardiologist 1. The FDA label for Plavix explicitly warns about premature discontinuation 7. If surgery is needed within the first 12 months, elective procedures should be deferred until DAPT is completed 5.
The Aspirin Exception
When clopidogrel must be stopped (e.g., for surgery), aspirin should be continued if at all possible and clopidogrel restarted as soon as feasible 4, 5. Studies show that stopping both agents simultaneously dramatically increases thrombosis risk, with median time to stent thrombosis of only 7 days 5.
After 12 Months: Aspirin Alone
Once clopidogrel is stopped at 12 months, aspirin 75-162 mg daily should be continued indefinitely 1, 3. This provides ongoing cardiovascular protection without the added bleeding risk of dual therapy. Recent evidence suggests clopidogrel monotherapy may be superior to aspirin monotherapy in the chronic maintenance phase 8, 9, but current guidelines still recommend aspirin as the standard long-term agent.